General opinion, Biotech and Risk Averse will not go hand on hand.
Their financial is relatively good
CRSP’s short-term assets exceed its long-term liabilities
CRSP’s operating cash flow is sufficient to service the company’s debt
CRSP’s debt relative to shareholder equity has decreased or remained constant compared to 5 years ago.
CRSP’s debt to equity ratio is considered acceptable
CRSP’s revenue has grown faster than the US Biotechnology industry average
Wall street Analyst price target
Min Forecast $132.00+29.42%
Avg Forecast $161.89+58.73%
Max Forecast $187.00+83.35%
But it is probably worthy a punt if the price drop significantly 100% below (say) the WA analyst avarage price target to offset the risk beeing in BioTech industry.
CRSP is one of the ARK Invest main holding.
But more institutional investors are dumping their shares in two consecutives quartal might be a red flag. So it might be important to do further investigation why they are dumping their shares